Pilot research shows nurse-led care management in rural primary care may reduce chronic pain interference, improving daily function through continuous support, safer medication use, and coordinated non-drug therapies.

Blood metabolic fingerprints may detect early arterial damage in people with HIV before imaging changes appear, enabling earlier cardiovascular risk prevention alongside long-term antiretroviral care.

Medically induced menopause from breast cancer treatment triggers abrupt hormone loss, intensifying symptoms, affecting fertility, and increasing long term bone, cardiovascular, and survivorship care challenges.

First U.S. transseptal AMEND annuloplasty implantation expands minimally invasive options for high-risk mitral regurgitation patients, replicating surgical repair anatomy without sternotomy and reshaping structural heart care.

Ferroptosis, an iron-driven lipid oxidation death pathway, shapes liver injury, fibrosis, and cancer, offering dual therapeutic potential to protect hepatocytes or selectively eliminate resistant tumor cells.

A newly identified molecular signature in polycythemia vera improves prediction of disease progression, enabling biologically informed risk stratification, personalized monitoring, and earlier intervention for high-risk patients.

Medicaid expansion improves breast cancer outcomes by increasing early-stage diagnoses, reducing late-stage disease, narrowing racial disparities, lowering mortality, and stabilizing health systems through earlier, affordable access to care.

New research clarifies rare mRNA vaccine–associated myocarditis arises from brief innate immune overactivation, guiding safer dosing, monitoring strategies, and next-generation vaccine design while preserving public confidence.

Wider use of targeted cancer drugs and immunotherapies is elevating ocular toxicity risk, requiring early recognition, multidisciplinary coordination, and proactive monitoring to protect vision without compromising cancer control.

Real-world data show about one-quarter of lupus patients achieve six-month remission with anifrolumab, supporting earlier targeted therapy, steroid reduction, and evolving care pathways for systemic lupus erythematosus.